Leerink Partnrs Has Optimistic Outlook of LXRX Q3 Earnings

Key Points

• Leerink Partners raised their earnings estimates for Lexicon Pharmaceuticals, projecting an EPS of ($0.05) for Q3 2025, compared to a prior estimate of ($0.09).
• Lexicon Pharmaceuticals reported a EPS of $0.01 for the most recent quarter, beating analyst expectations of ($0.08) by $0.09.
• Lexicon currently has a consensus rating of "Hold" among analysts, with a consensus price target of $3.23.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) - Research analysts at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for shares of Lexicon Pharmaceuticals in a report issued on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter, up from their previous estimate of ($0.09). The consensus estimate for Lexicon Pharmaceuticals' current full-year earnings is ($0.66) per share. Leerink Partnrs also issued estimates for Lexicon Pharmaceuticals' Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.17) EPS.

A number of other equities research analysts have also recently issued reports on LXRX. Wall Street Zen initiated coverage on Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Tuesday, June 24th. Finally, Citigroup upped their target price on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a "buy" rating in a research report on Thursday, August 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Lexicon Pharmaceuticals has an average rating of "Hold" and an average price target of $3.23.

Lexicon Pharmaceuticals Stock Performance

Lexicon Pharmaceuticals stock traded up $0.06 during trading hours on Monday, reaching $1.12. 2,050,808 shares of the company were exchanged, compared to its average volume of 8,844,003. The firm has a market cap of $405.19 million, a price-to-earnings ratio of -3.38 and a beta of 1.17. The company has a current ratio of 4.16, a quick ratio of 4.16 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $0.96 and a 200 day moving average of $0.72. Lexicon Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $2.18.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. The firm had revenue of $28.87 million during the quarter, compared to analysts' expectations of $4.87 million. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new position in shares of Lexicon Pharmaceuticals during the fourth quarter worth approximately $38,000. Schonfeld Strategic Advisors LLC raised its stake in shares of Lexicon Pharmaceuticals by 301.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock valued at $5,582,000 after purchasing an additional 5,676,021 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of Lexicon Pharmaceuticals in the fourth quarter valued at $355,000. Deutsche Bank AG raised its stake in shares of Lexicon Pharmaceuticals by 378.0% in the fourth quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 249,616 shares in the last quarter. Finally, Tang Capital Management LLC raised its stake in shares of Lexicon Pharmaceuticals by 750.3% in the fourth quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company's stock valued at $628,000 after purchasing an additional 750,268 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.